Company Description
Daré Bioscience, Inc., a biopharmaceutical company, develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health in the United States.
The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis.
It also develops Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert for the treatment of cervical intraepithelial neoplasia and other human papillomavirus related pathologies.
In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth.
Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; and DARE-GML, a multi-target antimicrobial agent.
Daré Bioscience, Inc. is headquartered in San Diego, California.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 23 |
| CEO | Sabrina Johnson |
Contact Details
Address: 3655 Nobel Drive, Suite 260 San Diego, California 92122 United States | |
| Phone | 858 926 7655 |
| Website | darebioscience.com |
Stock Details
| Ticker Symbol | DARE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001401914 |
| CUSIP Number | 23666P101 |
| ISIN Number | US23666P1012 |
| Employer ID | 20-4139823 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sabrina Martucci Johnson | Chief Executive Officer, President, Principal Financial Officer, Secretary and Director |
| MarDee J. Haring-Layton | Chief Accounting Officer |
| Mark Walters | Vice President of Operations |
| Dr. David Friend Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2025 | 8-K | Current Report |
| May 13, 2025 | 10-Q | Quarterly Report |
| Apr 24, 2025 | ARS | Filing |
| Apr 24, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 11, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 31, 2025 | 8-K | Current Report |
| Feb 14, 2025 | 8-K | Current Report |
| Feb 10, 2025 | 8-K | Current Report |